Affiliation:
1. Research Intern, Section of Molecular Pathology, Department of Pathology and Laboratory Medicine Cedars‐Sinai Medical Center California Los Angeles USA
2. Division of Molecular Pathology, Department of Pathology and Laboratory Medicine Cedars‐Sinai Medical Center California Los Angeles USA
3. Aaron Diamond AIDS Research Center Columbia University Vagelos College of Physicians and Surgeons New York New York USA
4. Department of Medicine Cedars‐Sinai Medical Center California Los Angeles USA
Abstract
AbstractBased upon clinical observations and recent reports, we anticipated there would be an inverse dose–response relationship between the severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral load and the time‐to‐positivity after application of the nasal swab sample in two popular home coronavirus disease 2019 (COVID‐19) antigen tests, BinaxNOW COVID‐19 Antigen Self‐Test and Flowflex COVID‐19 Antigen Home Test, both of which are sensitive to the nucleocapsid protein (NP). The relationship among the concentration of NP, WA1, and Omicron XBB.1.5 viral strains and the time‐to‐positive result by visual assessment in the tests was examined. The correlation between reverse transcription‐polymerase chain reaction cycle threshold (Ct) values and time‐to‐positivity in clinical samples (training set) also was determined. Strong inverse correlations were obtained between the concentration of the NP, WA1, XBB.1.5, Ct values for dilutions of both WA1 and XBB.1.5, as well as Ct values from the clinical samples and time‐to‐positivity in both antigen tests. The correlation between the actual and predicted Ct values interpolated from the training set was high with both tests in a second set of clinical samples. These results, together with those of other investigations with similar tests, suggest that the time‐to‐positive visual result in most, if not all, lateral flow COVID‐19 antigen tests can be utilized to estimate SARS‐CoV‐2 viral concentrations.
Reference23 articles.
1. fda.gov/medical‐devices/covid‐19‐emergency‐use‐authorizations‐medical‐devices/in‐vitro‐diagnostics‐euas‐antigen‐diagostic‐tests‐sars‐cov‐2. Accessed December 8 2023.
2. Lateral flow assays
3. Four rapid serum-urine combination assays of choriogonadotropin (hCG) compared and assessed for their utility in quantitative determinations of hCG
4. IDSA and AMP joint statement on the use of SARS‐CoV‐2 cycle threshold (Ct) values for clinical decision making. March 12 2021. www .idsociety.org.
5. Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco